Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
October 02, 2023 07:00 ET
|
Trevena, Inc.
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into...
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
September 06, 2023 07:01 ET
|
Trevena, Inc.
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION...
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
September 06, 2023 07:00 ET
|
Trevena, Inc.
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant...
Trevena Reports Second Quarter 2023 Results and Provides Business Update
August 14, 2023 07:00 ET
|
Trevena, Inc.
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for...
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
July 20, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
June 26, 2023 07:00 ET
|
Trevena, Inc.
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated...
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
May 31, 2023 07:00 ET
|
Trevena, Inc.
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first...
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones
May 30, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports First Quarter 2023 Results and Provides Business Update
May 15, 2023 07:00 ET
|
Trevena, Inc.
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million...
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
May 09, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...